secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001664710-25-000045
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Q1 net income $148.5M on Takeda license; cash $720.5M; KER-065 Phase 2 plan Q1 2026
--------------------------------------------------------------------------------

- Net income of $148.5M vs net loss of $43.1M YoY; revenue driven by Takeda license agreement.
- Research and development expenses $48.7M, up from $38.3M YoY, due to pipeline advancement.
- Cash and cash equivalents $720.5M expected to fund operations into 2029.
- Phase 1 KER-065 topline met objectives; plan to start Phase 2 in Q1 2026 after regulatory engagement.
- Phase 2 TROPOS trial of cibotercept (KER-012) in PAH data expected Q2 2025; Board reviewing strategic alternatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000045/0001664710-25-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000045/kros-20250506.htm
  HTML page:      https://secwatch.observer/filing/0001664710-25-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer